UnitedHealth (UNH) Price Target Raised to $492 by Bernstein on EPS Recovery
Bernstein raised its price target on UnitedHealth (UNH) to $492 from $444, citing an improved adjusted EPS outlook driven by a recovery in Medicare Advantage and higher target multiples.
UnitedHealth Group (NYSE: UNH) received a price target upgrade from Bernstein on May 27, with the firm raising its target to $492 from $444 while maintaining an Outperform rating. The new target implies a 27% upside from the previous close, reflecting optimism around the company's earnings recovery trajectory.
Bernstein's revision is tied to an improved adjusted EPS outlook, driven primarily by a recovery in Medicare Advantage enrollment and reimbursement trends. The firm also applied higher target multiples, noting that UnitedHealth's projected 16% adjusted EPS compound annual growth rate (CAGR) supports a higher valuation during this cyclical recovery phase. Separately, Barclays raised its price target on UNH to $429 from $373 on May 26, adding to the positive analyst sentiment. For traders tracking the healthcare sector, live price data and charts on NowPrice show how UNH shares are reacting to these analyst upgrades.
Looking ahead, investors will watch for upcoming Medicare Advantage rate announcements and quarterly enrollment data, which will be key to validating the recovery thesis. The broader managed care sector's performance will also be influenced by regulatory developments and utilization trends. UnitedHealth's ability to sustain its EPS growth trajectory will be critical for further upside toward the $492 target.